Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jodl

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Ceskoslovenska Gastroenterologie a Vyziva|March 1, 1980
[Functional digestive disorders. A group discussion at the meeting of the Czechoslovak Gastroenterologic and Nutrition Society on June 14 and 15, 1979 in Brno]Z Maratka, J Bitter, J Jodl, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 1985
Age and sex dependency of the biochemical indices of bone remodellingJ J Stĕpán, A Tesarová, T Havránek, et al.
Ceskoslovenska Pediatrie|December 1, 1990
[New recommendations for nutritional requirements of infants, children and adolescents in Czechoslovakia]I Kajaba, J Budlovský, A Dvorský, et al.
Casopis Lekaru Ceskych|April 10, 1992
[New recommendations for nutritional requirements for the Czechoslovak population]I Kajaba, J Budlovský, A Dvorský, et al.
The Journal of Chemical Physics|March 25, 2006
On the epsilon-zeta transition of nitrogenEugene Gregoryanz, Chrystèle Sanloup, Roberto Bini, et al.
Frontiers in Pharmacology|June 16, 2025
Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studiesMaximilian Feldmüller, Stefan J Jodl, Bart Ploeger, et al.
Dermatology and Therapy|September 4, 2025
Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized StudyStefan J Jodl, Margitta Worm, Frauke Friedrichs, et al.
Clinical and Translational Science|March 21, 2024
The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteersStefan J Jodl, Wouter Ten Voorde, Stefan Klein, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Ceskoslovenska Gastroenterologie a Vyziva|March 1, 1980
[Functional digestive disorders. A group discussion at the meeting of the Czechoslovak Gastroenterologic and Nutrition Society on June 14 and 15, 1979 in Brno]Z Maratka, J Bitter, J Jodl, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 1985
Age and sex dependency of the biochemical indices of bone remodellingJ J Stĕpán, A Tesarová, T Havránek, et al.
Ceskoslovenska Pediatrie|December 1, 1990
[New recommendations for nutritional requirements of infants, children and adolescents in Czechoslovakia]I Kajaba, J Budlovský, A Dvorský, et al.
Casopis Lekaru Ceskych|April 10, 1992
[New recommendations for nutritional requirements for the Czechoslovak population]I Kajaba, J Budlovský, A Dvorský, et al.
The Journal of Chemical Physics|March 25, 2006
On the epsilon-zeta transition of nitrogenEugene Gregoryanz, Chrystèle Sanloup, Roberto Bini, et al.
Frontiers in Pharmacology|June 16, 2025
Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studiesMaximilian Feldmüller, Stefan J Jodl, Bart Ploeger, et al.
Dermatology and Therapy|September 4, 2025
Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized StudyStefan J Jodl, Margitta Worm, Frauke Friedrichs, et al.
Clinical and Translational Science|March 21, 2024
The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteersStefan J Jodl, Wouter Ten Voorde, Stefan Klein, et al.
Pageof 5